Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients
This study, called SONCO, is looking at how a special type of genetic testing, called genomic sequencing, is being used for cancer patients in France. It uses two specific testing platforms, SeqOIA and AURAGEN, to see how these advanced tests affect a patient's care journey and treatment choices. Researchers are collecting important information on how quickly results are available, the quality of patient information, and the overall care provided. The aim is to understand the real-world impact of these tests to help shape future cancer care across France and make sure genomic testing is used in the best way possible for patients.
At a glance
What is this study about?
This study, called SONCO, is trying to understand how advanced genetic testing for cancer patients, known as genomic sequencing, is working in France. Think of genomic sequencing as a very detailed look at the genetic makeup of a person's cancer. The study is particularly interested in two specific testing services, SeqOIA and AURAGEN, which are part of France's plan to improve healthcare using genetics.
The main goal is to see if these detailed genetic tests genuinely help doctors make better treatment decisions and improve how patients are cared for. The researchers are looking at several key things: how quickly patients get their results, if the information given to patients is clear and helpful, and if the overall quality of care changes after these tests. They gather information from various sources, including reports from specialist cancer teams and patient hospital records.
Ultimately, the findings from this study will help healthcare leaders in France make important decisions about how to best use genomic testing in the future. It will also help them plan for the resources needed to make these advanced tests available to more patients, ensuring that cancer care continues to improve and evolve.
Key takeaways
- The SONCO study is about improving cancer care using advanced genetic tests.
- It aims to see how these tests impact treatment and patient care.
- Data collected will help shape future healthcare decisions in France.
- The study doesn't involve any new treatments or tests for patients.
- Findings will help ensure better use of genetic information for cancer patients.
Who may be eligible?
To be part of this study, you would generally need to be a patient diagnosed with cancer. Your cancer specialist team (often called a Multidisciplinary Tumor Board or MTD) would need to have agreed that this advanced genetic testing is suitable for you.
Another important requirement is that you must have given your permission for your medical information and genetic test results to be used for research purposes. You also can't have said that you don't want your data used for research.
Anyone who has chosen not to have their information used for research, or if their specialist team has not approved the genetic testing, would not be included in this study.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Do I have a cancer diagnosis?
- Has my care team discussed advanced genetic testing for my cancer?
- Has my specialist cancer team agreed that this genetic testing is suitable for me?
- Have I agreed to my medical information being used for research?
- Have I NOT said that I don't want my data used for research?
What does participation involve?
As an observational study, taking part typically won't involve extra appointments or changes to your medical care. The researchers will be collecting information that is already part of your routine cancer care. This includes details from your hospital notes, such as your diagnosis and treatment plans, and reports from your genetic tests and specialist cancer team meetings. You won't be asked to take any new medication or have additional assessments specifically for the study. The total duration of your involvement would depend on your treatment pathway and how long your data is collected for, but it won't add any extra time to your medical appointments.
Potential risks and benefits
Locations (3)
- Centre Leon BerardVerified postcodeLyon, France· Recruiting
- APHP Hôtel Dieu URC Economie de la sante /URC ECOVerified postcodeParis, France· Active not recruiting
- HOPITAL AP-HP CochinVerified postcodeParis, France· Recruiting
Common questions
What is genomic sequencing?
It's a detailed genetic test that looks at the full genetic makeup of a cancer to help doctors understand it better and choose the best treatments.
Will this study change my cancer treatment?
No, this study only collects information from your existing medical care. It won't change your diagnosis or treatment plan.
Who is running this study?
This study is part of the French Genomic Medicine Plan 2025, involving key genetic testing platforms like SeqOIA and AURAGEN.
Is my personal information kept private?
Yes, strict rules are in place to ensure your medical and genetic data is anonymised and kept confidential for research purposes only.
Why is this study important?
It helps make sure that advanced genetic testing for cancer is used in the best way possible, benefiting all cancer patients in the long run.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.